Welcome!

News Feed Item

RXi Pharmaceuticals Reports Full Year 2013 Financial Results

WESTBOROUGH, Mass., March 28, 2014 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today reported its financial results for the full year 2013, and provided a business update.

RXi Pharmaceuticals.

"RXi's proprietary self-delivering RNAi platform (sd-rxRNA®) provided a solid foundation for our continued product development efforts in 2013, and continues to offer potential opportunities for future value creation," said Dr. Geert Cauwenbergh, President and CEO of the Company. He added that, "Conservative use of our available cash, combined with the professional strengths of our employees and the support of our shareholders, has been instrumental in moving RXI-109, our anti-scarring compound, into Phase 2 clinical studies, from which we expect to see the first results in the course of 2014."

Fourth Quarter 2013 and Recent Company Highlights

  • Announcement of the Start of our First Phase 2 Clinical Trial: In November 2013, we announced the initiation and enrollment of the first patient in a Phase 2 study with the anti-scarring product RXI-109. In this study, patients with a long hypertrophic scar in the lower abdominal area are eligible to receive scar revision surgery and subsequent treatment with RXI-109 in one of two treatment regimens. Patients will receive RXI-109 or placebo on a blinded basis at the distal ends of the revised scar, leaving a central untreated section of the scar. Each patient's revised scar will provide the opportunity to compare the appearance of the revised areas after treatment with RXI-109 or placebo or when left untreated.
  • Signing of a Distribution Agreement for RXI-109 in the European Union with Ethicor Ltd.: In November 2013, we signed a distribution agreement with Ethicor Ltd. ("Ethicor"), a UK based unlicensed medicinal products ("Specials") pharmaceutical company. The agreement provides Ethicor with the distribution rights to RXI-109 in the European Union, with the possibility to negotiate in the future to extend such rights to other regions of the world, excluding the United States, Canada and Mexico. Should we obtain marketing authorization for RXI-109 in any of the countries covered by the agreement, we have the option to terminate the agreement with respect to each such country in which marketing authorization has been obtained. The gross profits generated from any sales of RXI-109 by Ethicor will be shared between us and Ethicor.
  • Announcement of mRNA Data of an Additional Cohort in our Second Phase 1 Clinical Trial: In December 2013, we announced the results from additional cohorts in our second Phase 1 clinical trial, Study 1202. In the additional fourth cohort of this study, RXI-109 was dosed over the initial 2-week period following the incision which resulted in a 50% reduction of CTGF mRNA expression compared to the placebo when measured three days after the last dose. In the fifth cohort of the study, the dosing period was delayed by two weeks after the incisions were made. No additional benefit was seen on mRNA reduction. Multiple dermal injections were well tolerated at all doses, and treatment with RXI‑109 resulted in dose-dependent silencing of CTGF mRNA in the treated areas.
  • Announcement of Listing on The NASDAQ Capital Market: Announced in February 2014 that the Company received approval to list its common stock on The NASDAQ Capital Market. The Company's common stock commenced trading under the same ticker symbol, "RXII," on The NASDAQ Capital Market effective at the opening of trading on Tuesday, February 11, 2014.
  • Grant of Key Patent Related to Self-Delivering Technology for the Treatment of Fibrotic Disorders: In March 2014, the Company announced that it had been granted a patent by the U.S. Patent and Trademark Office on its unique self-delivering RNAi compounds (sd-rxRNA®), for the treatment of fibrosis. The patent covers the use of sd-rxRNAs targeting CTGF for the treatment of fibrotic disorders. The patent (U.S. Patent Number 8,664,189) is scheduled to expire in 2029.

Selected Full Year Financial Highlights

Cash and Cash Equivalents

At December 31, 2013, RXi had cash, cash equivalents, and short-term investments of approximately $14.4 million, compared with $5.1 million at December 31, 2012.

Net Loss and Net Loss Applicable to Common Stockholders

Net loss for the year ended December 31, 2013 was $20.9 million, including $2.0 million in non-cash share-based compensation expense, compared with a net loss of $12.9 million, including $1.0 million in non-cash share-based compensation expense, for the year ended December 31, 2012. The increase in the net loss of $8.0 million was primarily attributable to a one-time non-cash charge of $12.3 million related to the fair value of common shares issued in exchange for certain RNAi-related assets from OPKO Health, Inc. as compared with a one-time non-cash charge of $6.2 million related to the fair value of common shares issued in exchange for patent and technology rights for the same period in 2012.

Net loss applicable to common stockholders for the year ended December 31, 2013 was $29.5 million compared with a net loss applicable to common stockholders of $25.7 million for the comparable period in 2012. The increase in net loss applicable to common stockholders of $3.8 million was primarily attributable to the aforementioned increase in net loss as compared to prior year and an increase of $5.3 million related to the fair value of Series A and Series A-1 Preferred Stock offset by a decrease of $9.5 million related to a one-time charge for the beneficial conversion feature of the Series A Preferred Stock recorded in the second quarter of 2012.

Revenues

Total revenues for the year ended December 31, 2013 were $0.4 million as compared with $0.1 million for the comparable period in 2012. The increase in total revenues for the year ended December 31, 2013 was due to the recognition of work completed on the Company's government grants during the period.  

Research and Development Expenses

Research and development expenses for the year ended December 31, 2013 were $17.7 million, compared with $10.5 million for the year ended December 31, 2012. The increase of $7.2 million was primarily due to increases of $6.1 million in expense related to the fair value of common shares issued in exchange for patent and technology rights, $0.7 million in research and development expenses largely due to costs related to the manufacture of RXI-109 for use in the Company's on-going clinical trials and $0.4 million in employee stock-based compensation expense.

General and Administrative Expenses

General and administrative expenses for the year ended December 31, 2013 were $3.7 million, compared with $2.6 million for the comparable period in 2012. The increase in general and administrative expenses of $1.1 million was primarily due to an increase of $0.6 in employee stock-based compensation and $0.5 million in general and administrative expenses due to an increase in employee headcount, employee compensation and benefits, increases in Board fees, the annual Delaware franchise tax for 2013 and professional services such as outside contractors and consultants.

Series A and Series A-1 Preferred Stock and Dividends

Accretion of Series A and Series A-1 Preferred Stock and dividends was $8.6 million for the year ended December 31, 2013, compared with $12.8 million accretion of Series A and Series A-1 Preferred Stock and dividends for the comparable period in 2012. The decrease of $4.2 million is due to the one-time charge of $9.5 million related to the beneficial conversion feature of the Series A Preferred Stock during the same period in the prior year offset by an increase of $5.3 million in Series A and Series A-1 Preferred Stock dividends due to changes in the Company's closing common stock price on the dividend payment dates and the number of preferred shares earning dividends each year.

About RXi Pharmaceuticals Corporation

RXi Pharmaceuticals Corporation (NASDAQ: RXII) is a biotechnology company focused on discovering, developing and commercializing innovative therapies based on its proprietary, self-delivering RNAi platform. Therapeutics that use RNA interference, or "RNAi," have great promise because of their ability to down-regulate, the expression of a specific gene that may be over-expressed in a disease condition. Building on the pioneering work of scientific founder and Nobel Laureate Dr. Craig Mello, a member of the RXi Scientific Advisory Board, RXi's first RNAi product candidate, RXI-109, targets connective tissue growth factor (CTGF) to reduce dermal scarring (fibrosis), entered into human clinical trials in June 2012. For more information, please visit www.rxipharma.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "intend," "believe," "expect," "may," "should," "designed to," "will" and similar references. Such statements include, but are not limited to, statements about: our ability to successfully develop RXI-109 and our other product candidates; the timing and future success of our clinical trials with RXI-109; our expectation that we will complete our Phase 2 clinical trials for RXI-109 within anticipated time periods and budgets; our ability to implement cost-saving measures and statements about other future expectations. Forward-looking statements are neither historical facts nor assurances of future performance. Instead they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others: the risk that our clinical trial with RXI-109 may not be successful in evaluating the safety and tolerability of RXI-109 or providing preliminary evidence of the reduction of formation of surgical scars; the successful and timely completion of clinical studies; uncertainties regarding the regulatory process; the availability of funds and resources to pursue our research and development projects, including our clinical trials with RXI-109; and those identified under "Risk Factors" in the Company's most recently filed Annual Report on Form 10-K, Quarterly Report on Form 10-Q and in other filings the Company periodically makes with the SEC. The Company does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this press release. 

Contacts

RXi Pharmaceuticals Corporation
Tamara McGrillen, 508-929-3646
[email protected] 

 

RXi PHARMACEUTICALS CORPORATION


(A Development Stage Company)


CONDENSED STATEMENTS OF OPERATIONS


(Amounts in thousands, except share and per share data)













Year Ended


Year Ended



December 31,


December 31,



2013


2012







Total revenues

$                 399


$                  97







Research and development expenses

17,651


10,451


General and administrative expenses

3,697


2,621


Operating loss

(20,949)


(12,975)


Interest income (expense)

24


(30)


Other income


125


Net loss

(20,925)


(12,880)


 Accretion of Series A and Series A-1 preferred stock and dividends

(8,610)


(12,815)


Net loss applicable to common stockholders

$          (29,535)


$        (25,695)


    Net loss per common share applicable to common stockholders:





Basic and diluted loss per share

$             (2.88)


$            (5.62)


Weighted average common shares outstanding:





Basic and diluted

10,263,954


4,573,787


 

 

RXi PHARMACEUTICALS CORPORATION


(A Development Stage Company)


CONDENSED BALANCE SHEETS


(Amounts in thousands)





December 31,


December 31,



2013


2012


ASSETS            





Current assets:





Cash and cash equivalents

$           11,390


$          5,127


Restricted cash

50


53


Short-term investments

3,000



Prepaid expenses and other current assets

303


212


Total current assets

14,743


5,392


Equipment and furnishings, net

177


198


Other assets

18


2







Total assets

$            14,938


$         5,592







LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)





Current liabilities:





Accounts payable

$               163


$            416


Accrued expenses and other current liabilities

1,795


767


Deferred revenue

118


491


Current maturities of capital lease obligations


5


Total current liabilities

2,076


1,679


Deferred revenue, net of current portion


27


Total liabilities

2,076


1,706


Total convertible preferred stock

7,920


9,726


Total stockholders' equity (deficit)

4,942


(5,840)


Total liabilities, convertible preferred stock and stockholders' equity (deficit)

$            14,938


$         5,592


 

Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO

SOURCE RXi Pharmaceuticals Corporation

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Multiple data types are pouring into IoT deployments. Data is coming in small packages as well as enormous files and data streams of many sizes. Widespread use of mobile devices adds to the total. In this power panel at @ThingsExpo, moderated by Conference Chair Roger Strukhoff, panelists looked at the tools and environments that are being put to use in IoT deployments, as well as the team skills a modern enterprise IT shop needs to keep things running, get a handle on all this data, and deliver...
After more than five years of DevOps, definitions are evolving, boundaries are expanding, ‘unicorns’ are no longer rare, enterprises are on board, and pundits are moving on. Can we now look at an evolution of DevOps? Should we? Is the foundation of DevOps ‘done’, or is there still too much left to do? What is mature, and what is still missing? What does the next 5 years of DevOps look like? In this Power Panel at DevOps Summit, moderated by DevOps Summit Conference Chair Andi Mann, panelists loo...
In his session at @ThingsExpo, Eric Lachapelle, CEO of the Professional Evaluation and Certification Board (PECB), provided an overview of various initiatives to certify the security of connected devices and future trends in ensuring public trust of IoT. Eric Lachapelle is the Chief Executive Officer of the Professional Evaluation and Certification Board (PECB), an international certification body. His role is to help companies and individuals to achieve professional, accredited and worldwide re...
While DevOps most critically and famously fosters collaboration, communication, and integration through cultural change, culture is more of an output than an input. In order to actively drive cultural evolution, organizations must make substantial organizational and process changes, and adopt new technologies, to encourage a DevOps culture. Moderated by Andi Mann, panelists discussed how to balance these three pillars of DevOps, where to focus attention (and resources), where organizations might...
Amazon started as an online bookseller 20 years ago. Since then, it has evolved into a technology juggernaut that has disrupted multiple markets and industries and touches many aspects of our lives. It is a relentless technology and business model innovator driving disruption throughout numerous ecosystems. Amazon’s AWS revenues alone are approaching $16B a year making it one of the largest IT companies in the world. With dominant offerings in Cloud, IoT, eCommerce, Big Data, AI, Digital Assista...
New competitors, disruptive technologies, and growing expectations are pushing every business to both adopt and deliver new digital services. This ‘Digital Transformation’ demands rapid delivery and continuous iteration of new competitive services via multiple channels, which in turn demands new service delivery techniques – including DevOps. In this power panel at @DevOpsSummit 20th Cloud Expo, moderated by DevOps Conference Co-Chair Andi Mann, panelists examined how DevOps helps to meet the de...
Both SaaS vendors and SaaS buyers are going “all-in” to hyperscale IaaS platforms such as AWS, which is disrupting the SaaS value proposition. Why should the enterprise SaaS consumer pay for the SaaS service if their data is resident in adjacent AWS S3 buckets? If both SaaS sellers and buyers are using the same cloud tools, automation and pay-per-transaction model offered by IaaS platforms, then why not host the “shrink-wrapped” software in the customers’ cloud? Further, serverless computing, cl...
You know you need the cloud, but you’re hesitant to simply dump everything at Amazon since you know that not all workloads are suitable for cloud. You know that you want the kind of ease of use and scalability that you get with public cloud, but your applications are architected in a way that makes the public cloud a non-starter. You’re looking at private cloud solutions based on hyperconverged infrastructure, but you’re concerned with the limits inherent in those technologies.
The taxi industry never saw Uber coming. Startups are a threat to incumbents like never before, and a major enabler for startups is that they are instantly “cloud ready.” If innovation moves at the pace of IT, then your company is in trouble. Why? Because your data center will not keep up with frenetic pace AWS, Microsoft and Google are rolling out new capabilities. In his session at 20th Cloud Expo, Don Browning, VP of Cloud Architecture at Turner, posited that disruption is inevitable for comp...
No hype cycles or predictions of zillions of things here. IoT is big. You get it. You know your business and have great ideas for a business transformation strategy. What comes next? Time to make it happen. In his session at @ThingsExpo, Jay Mason, Associate Partner at M&S Consulting, presented a step-by-step plan to develop your technology implementation strategy. He discussed the evaluation of communication standards and IoT messaging protocols, data analytics considerations, edge-to-cloud tec...
"When we talk about cloud without compromise what we're talking about is that when people think about 'I need the flexibility of the cloud' - it's the ability to create applications and run them in a cloud environment that's far more flexible,” explained Matthew Finnie, CTO of Interoute, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
IoT solutions exploit operational data generated by Internet-connected smart “things” for the purpose of gaining operational insight and producing “better outcomes” (for example, create new business models, eliminate unscheduled maintenance, etc.). The explosive proliferation of IoT solutions will result in an exponential growth in the volume of IoT data, precipitating significant Information Governance issues: who owns the IoT data, what are the rights/duties of IoT solutions adopters towards t...
Wooed by the promise of faster innovation, lower TCO, and greater agility, businesses of every shape and size have embraced the cloud at every layer of the IT stack – from apps to file sharing to infrastructure. The typical organization currently uses more than a dozen sanctioned cloud apps and will shift more than half of all workloads to the cloud by 2018. Such cloud investments have delivered measurable benefits. But they’ve also resulted in some unintended side-effects: complexity and risk. ...
It is ironic, but perhaps not unexpected, that many organizations who want the benefits of using an Agile approach to deliver software use a waterfall approach to adopting Agile practices: they form plans, they set milestones, and they measure progress by how many teams they have engaged. Old habits die hard, but like most waterfall software projects, most waterfall-style Agile adoption efforts fail to produce the results desired. The problem is that to get the results they want, they have to ch...
With the introduction of IoT and Smart Living in every aspect of our lives, one question has become relevant: What are the security implications? To answer this, first we have to look and explore the security models of the technologies that IoT is founded upon. In his session at @ThingsExpo, Nevi Kaja, a Research Engineer at Ford Motor Company, discussed some of the security challenges of the IoT infrastructure and related how these aspects impact Smart Living. The material was delivered interac...